Gilead Addresses HCV Vulnerability With Strong Genotype 3 Data
This article was originally published in The Pink Sheet Daily
Gilead is looking at second-generation two- and three-drug combinations to stem the weaknesses of Harvoni, particularly in genotype 3, but Merck and AbbVie also are focusing on this large subgroup of HCV. Meanwhile, Bristol is working to bolster its indication in genotype 3.
Register for our free email digests: